EYPT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of -49.65%. EyePoint Pharmaceuticals's return on equity of -50.67% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 364.65%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than EyePoint Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. EyePoint Pharmaceuticals's net income of -$29.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.98x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of -2357.27%. EyePoint Pharmaceuticals's return on equity of -50.67% beat Palatin Technologies's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 364.65%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than EyePoint Pharmaceuticals, analysts believe Palatin Technologies is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are larger than Palatin Technologies quarterly revenues of $350K. EyePoint Pharmaceuticals's net income of -$29.4M is lower than Palatin Technologies's net income of -$7.8M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of 36.03%. EyePoint Pharmaceuticals's return on equity of -50.67% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 364.65%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.82%. Given that EyePoint Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. EyePoint Pharmaceuticals's net income of -$29.4M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.98x versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of --. EyePoint Pharmaceuticals's return on equity of -50.67% beat Theriva Biologics's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 364.65%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6056.46%. Given that Theriva Biologics has higher upside potential than EyePoint Pharmaceuticals, analysts believe Theriva Biologics is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are larger than Theriva Biologics quarterly revenues of --. EyePoint Pharmaceuticals's net income of -$29.4M is lower than Theriva Biologics's net income of -$7.7M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.98x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.